keyword
MENU ▼
Read by QxMD icon Read
search

Tumor infiltrating lymphocyte breast

keyword
https://www.readbyqxmd.com/read/29239188/-evaluation-of-inflammatory-cells-tumor-infiltrating-lymphocytes-in-solid-tumors
#1
P Dundr, K Němejcová, M Bártů, R Matěj, Z Rohan, I Tichá
BACKGROUND: The tumor microenvironment plays an important role in tumorigenesis and the tumor-host relationship. An important part of the tumor microenvironment is inflammatory infiltration. Its evaluation in solid tumors has prognostic meaning and appears also to be predictive of outcome, which is particularly important for predicting responses to immune checkpoint inhibitors. However, the methodology used to assess inflammatory infiltration is problematic, because it has been standardized only for certain types of tumors...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29233824/role-for-immune-therapy-in-advanced-breast-cancer
#2
(no author information available yet)
In a phase Ib/II trial, adding the PD-1 inhibitor pembrolizumab to trastuzumab showed clinical benefit in patients with advanced HER2-positive breast cancer who had developed resistance to trastuzumab. The study also identified tumor-infiltrating lymphocyte levels as a potential biomarker of response to treatment.
December 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29229854/interferon-beta-represses-cancer-stem-cell-properties-in-triple-negative-breast-cancer
#3
Mary R Doherty, HyeonJoo Cheon, Damian J Junk, Shaveta Vinayak, Vinay Varadan, Melinda L Telli, James M Ford, George R Stark, Mark W Jackson
Triple-negative breast cancer (TNBC), the deadliest form of this disease, lacks a targeted therapy. TNBC tumors that fail to respond to chemotherapy are characterized by a repressed IFN/signal transducer and activator of transcription (IFN/STAT) gene signature and are often enriched for cancer stem cells (CSCs). We have found that human mammary epithelial cells that undergo an epithelial-to-mesenchymal transition (EMT) following transformation acquire CSC properties. These mesenchymal/CSCs have a significantly repressed IFN/STAT gene expression signature and an enhanced ability to migrate and form tumor spheres...
December 11, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29224274/-correlation-analysis-of-pd-l1-expression-and-prognosis-in-triple-negative-breast-cancers
#4
B J Pan, C Xu, G Q Ping, G X Song, W M Zhang, C Wang, Z H Zhang
Objective: To investigate the relationship between PD-L1 expression and the clinicopathologic features and prognosis in triple-negative breast carcinomas (TNBC). Methods: All 142 cases of TNBC were collected from the First Affiliated Hospital of Nanjing Medical University from February 2011 to December 2014, and the surgical excision or biopsy specimens from patients without chemotherapy and radiotherapy were included. Histopathologic analysis of stromal tumor infiltrating lymphocyte (sTIL) was performed on HE sections, and PD-L1 immunohistochemical staining was done with MaxVision...
December 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29222623/tumor-infiltrating-lymphocytes-in-breast-cancer-patients-with-progressive-disease-during-neoadjuvant-chemotherapy
#5
Jacques Raphael, S Nofech-Mozes, T Paramsothy, N Li, S Gandhi
A minority of breast cancer (BC) patients progress during neoadjuvant chemotherapy (NCT). The aim of this study was to assess the value of Tumor infiltrating lymphocytes (TILs) in such a high-risk population where valid biomarkers are eagerly needed. A retrospective review identified BC patients who either progressed during NCT or achieved a pathologic complete response (pCR). An experienced BC pathologist semi-quantified stromal TILs in pre-treatment core biopsies using hematoxylin and eosin stained slides...
December 8, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29198959/evaluation-of-immune-reaction-and-pd-l1-expression-using-multiplex-immunohistochemistry-in-her2-positive-breast-cancer-the-association-with-response-to-anti-her2-neoadjuvant-therapy
#6
Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M Banks, Anil V Parwani, Zaibo Li
BACKGROUND: Immune reaction with tumor-infiltrating lymphocytes (TILs) has been extensively investigated in breast cancer. Programmed cell death 1 and its ligand (PD-L1) are key physiologic suppressors of cytotoxic immune reaction. However, the combination of TILs with PD-L1 expression has not been well studied in breast cancer. PATIENTS AND METHODS: A multi-color immunohistochemical multiplex assay simultaneously detecting PD-L1, CD8, and CD163 was performed on biopsy whole sections from 123 HER2-positive (HER2+) breast cancers, including 64 treated with anti-HER2 neoadjuvant therapy and subsequent resection...
November 9, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29185202/tumor-infiltrating-lymphocytes-affect-the-efficacy-of-trastuzumab-based-treatment-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#7
Hiroaki Inoue, Rie Horii, Yoshinori Ito, Takuji Iwase, Shinji Ohno, Futoshi Akiyama
BACKGROUND: Immune responses play an important role in interrupting the progression of cancer cells. Tumor-infiltrating lymphocytes (TILs) are basic components of the immune system. In triple negative breast cancer, increased number of TILs is associated with excellent prognosis and response of chemotherapy. Here, we investigated whether TILs affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHODS: The study included 97 patients with stage I-III HER2-positive breast cancer...
November 28, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29181007/interplay-between-natural-killer-cells-and-anti-her2-antibodies-perspectives-for-breast-cancer-immunotherapy
#8
REVIEW
Aura Muntasell, Mariona Cabo, Sonia Servitja, Ignasi Tusquets, María Martínez-García, Ana Rovira, Federico Rojo, Joan Albanell, Miguel López-Botet
Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy significantly improves relapse-free and overall survival in patients with early-stage and advanced disease. Nonetheless, considerable proportions of patients develop resistance to treatment, highlighting the need for additional and co-adjuvant therapeutic strategies. HER2-specific antibodies can trigger natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity and indirectly enhance the development of tumor-specific T cell immunity; both mechanisms contributing to their antitumor efficacy in preclinical models...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29168430/triple-negative-breast-cancer-prognostic-role-of-immune-related-factors-a-systematic-review
#9
Elisabeth Specht Stovgaard, Dorte Nielsen, Estrid Hogdall, Eva Balslev
PURPOSE: Treatment of breast cancer has been increasingly successful in recent years with the advent of HER2-receptor targeted treatment and endocrine treatment. However, the triple negative subgroup of breast cancer (TNBC) (estrogen-, progesterone- and HER2-receptor negative) still lacks targeted treatment options. TNBC is a type of breast cancer that often affects younger women, and generally has a worse prognosis than other types of breast cancer. Recently, the complex role of the immune system in cancer growth, elimination and metastasis has been the object of increased attention...
November 23, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29168428/standardized-assessment-of-tumor-infiltrating-lymphocytes-in-breast-cancer-an-evaluation-of-inter-observer-agreement-between-pathologists
#10
Trine Tramm, Tina Di Caterino, Anne-Marie B Jylling, Giedrius Lelkaitis, Anne-Vibeke Lænkholm, Péter Ragó, Tomasz P Tabor, Maj-Lis M Talman, Emmanouela Vouza
INTRODUCTION: In breast cancer, there is a growing body of evidence that tumor-infiltrating lymphocytes (TILs) may have clinical utility and may be able to direct clinical decisions for subgroups of patients. Clinical utility is, however, not sufficient for warranting the implementation of a new biomarker in the routine practice, and evaluation of the analytical validity is needed, including testing the reproducibility of decentralized assessment of TILs. The aim of this study was to evaluate the inter-observer agreement of TILs assessment using a standardized method, as proposed by the International TILs Working Group 2014, applied to a cohort of breast cancers reflecting an average breast cancer population...
November 23, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29168063/abundant-tumor-infiltrating-lymphocytes-after-primary-systemic-chemotherapy-predicts-poor-prognosis-in-estrogen-receptor-positive-her2-negative-breast-cancers
#11
Takahiro Watanabe, Akira I Hida, Natsuko Inoue, Michiko Imamura, Yukie Fujimoto, Kouhei Akazawa, Seiichi Hirota, Yasuo Miyoshi
PURPOSE: The therapeutic effect of systemic treatment for breast cancer (BC) generally depends on its intrinsic subtypes. In addition, tumor infiltrating lymphocytes (TILs) are considered to be an independent factor for tumor shrinkage and disease prognosis. High TILs at baseline or after primary systemic chemotherapy are reported to be associated with better survival in triple-negative or human epithelial growth factor receptor 2 (HER2)-positive BCs. However, the prognostic value of TILs in estrogen receptor (ER)-positive and HER2-negative (ER+/HER2-) BC is still controversial...
November 22, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29163490/immune-checkpoint-molecules-on-tumor-infiltrating-lymphocytes-and-their-association-with-tertiary-lymphoid-structures-in-human-breast-cancer
#12
Cinzia Solinas, Soizic Garaud, Pushpamali De Silva, Anaïs Boisson, Gert Van den Eynden, Alexandre de Wind, Paolo Risso, Joel Rodrigues Vitória, François Richard, Edoardo Migliori, Grégory Noël, Hugues Duvillier, Ligia Craciun, Isabelle Veys, Ahmad Awada, Vincent Detours, Denis Larsimont, Martine Piccart-Gebhart, Karen Willard-Gallo
There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer (BC), particularly in the triple-negative subtype where unmet treatment needs remain. This study was designed to analyze the expression, localization, and prognostic role of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, and TIM3 in primary BC. Gene expression analysis using the METABRIC microarray dataset found that all six immune checkpoint molecules are highly expressed in basal-like and HER2-enriched compared to the other BC molecular subtypes...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29156891/investigating-the-role-of-tumor-infiltrating-lymphocytes-in-advanced-her2-positive-breast-cancer
#13
EDITORIAL
Stephen J Luen, Sherene Loi
No abstract text is available yet for this article.
November 14, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29151971/the-predictive-and-prognostic-role-of-stromal-tumor-infiltrating-lymphocytes-in-her2-positive-breast-cancer-with-trastuzumab-based-treatment-a-meta-analysis-and-systematic-review
#14
Tao Xu, Bang-Shun He, Xiang-Xiang Liu, Xiu-Xiu Hu, Kang Lin, Yu-Qin Pan, Hui-Ling Sun, Hong-Xin Peng, Xiao-Xiang Chen, Shu-Kui Wang
Background Tumor-infiltrating lymphocytes (TILs) are white blood cells that have left the bloodstream and migrated into a tumor, involving in the prognosis of breast cancer (BC) patients. Published studies reported the value of TILs in patients with HER2-positive receiving trastuzumab-based treatment. However, the results obtained remain controversial. Here, we conducted this study to explore the predictive and prognostic role of TILs for HER2-positive BC patients receiving trastuzumab therapies. Method To identify the related published studies, a comprehensive literature search dating up to July 2017 was performed in the databases of PubMed, PMC, Web of Science and China National Knowledge Infrastructure (CNKI) according to predefined selection criteria...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29137398/prognostic-significance-of-pd-l1-expression-and-tumor-infiltrating-lymphocyte-in-surgically-resectable-non-small-cell-lung-cancer
#15
Gen Lin, Xirong Fan, Weifeng Zhu, Cheng Huang, Wu Zhuang, Haipeng Xu, Xiandong Lin, Dan Hu, Yunjian Huang, Kan Jiang, Qian Miao, Chao Li
Programmed death ligand 1 (PD-L1) expression is a predictive biomarker of the success of PD-1/PD-L1 inhibitor therapy for patients with advanced non-small cell lung cancer (NSCLC) but its role as a prognostic marker for early stage resectable NSCLC remains unclear. Here, we studied PD-L1 expression and tumor infiltrating lymphocytes (TILs) in surgically resectable NSCLC and correlate the finding with clinicopathological features and patient outcomes. Total of 170 archival samples of resectable NSCLC were probed for PD-L1 expression using the clone 22C3 pharmDx kit...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29129094/rational-combination-of-immunotherapy-for-triple-negative-breast-cancer-treatment
#16
Chia-Wei Li, Seung-Oe Lim, Jennifer L Hsu, Mien-Chie Hung
Recent evidence indicates that tumor infiltrating lymphocytes (TILs), including cytotoxic T cells, are present in the tumor microenvironment of triple-negative breast cancers (TNBC). Despite the presence of cytotoxic T cells, these tumors still develop, progress, and metastasize, suggesting evasion of immune response. One mechanism of immunosuppression is the presence of the T cell inhibitory molecule, programmed death protein 1 (PD-1), on infiltrating T cells and its cognate ligand programmed death ligand 1 (PD-L1) on tumor cells, myeloid dendritic cells (DCs), and macrophages, in the tumor microenvironment...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29126881/triple-negative-breast-cancer-key-role-of-tumor-associated-macrophages-in-regulating-the-activity-of-anti-pd-1-pd-l1-agents
#17
REVIEW
Matteo Santoni, Emanuela Romagnoli, Tiziana Saladino, Laura Foghini, Stefania Guarino, Marco Capponi, Massimo Giannini, Paolo Decembrini Cognigni, Gerardo Ferrara, Nicola Battelli
Triple-negative breast cancer (TNBC) is associated with a poor prognosis, due to its aggressive behaviour and lack of effective targeted therapies. Immunocheckpoint inhibitors, such as anti-programmed cell death 1 (PD-1) and anti-PD-ligand(L)1 agents, are in course of investigation in TNBC, used alone or in combination with other systemic or local approaches. However, the high cost of these drugs and the lack of validated predictive biomarkers support the development of strategies aimed to overcome resistance and optimize the efficacy of these approaches...
November 7, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29123960/the-sting-agonist-dmxaa-triggers-a-cooperation-between-t-lymphocytes-and-myeloid-cells-that-leads-to-tumor-regression
#18
Julia M Weiss, Marion V Guérin, Fabienne Regnier, Gilles Renault, Isabelle Galy-Fauroux, Lene Vimeux, Vincent Feuillet, Elisa Peranzoni, Maxime Thoreau, Alain Trautmann, Nadège Bercovici
Regressing tumors are usually associated with a large immune infiltrate, but the molecular and cellular interactions that govern a successful anti-tumor immunity remain elusive. Here, we have triggered type I Interferon (IFN) signaling in a breast tumor model (MMTV-PyMT) using 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a ligand of the STimulator of Interferon Genes, STING. The 2 main events rapidly triggered by DMXAA in transplanted PyMT tumors are 1) the disruption of the tumor vasculature, followed by hypoxia and cell death; 2) the release of chemokines...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29122657/diagnostic-significance-of-intratumoral-cd8-tumor-infiltrating-lymphocytes-in-medullary-carcinoma
#19
Fumie Igari, Eiichi Sato, Yoshiya Horimoto, Yuka Takahashi, Tatsuya Isomura, Atsushi Arakawa, Shigehisa Kitano, Mitsue Saito
Invasive ductal carcinomas of breast with marked stromal lymphocytic infiltration have come to be classified as lymphocyte predominant breast cancer (LPBC) because it obtains high pathological complete response rates with neoadjuvant chemotherapy. Medullary carcinoma (MC), which is independent from LPBC, is a rare histological subtype of invasive breast carcinoma accompanied by abundant lymphoplasmacytic infiltration as LPBC. Although MC shows marked cellular and structural atypia, it usually has a favorable outcome...
November 6, 2017: Human Pathology
https://www.readbyqxmd.com/read/29120748/doubling-down-on-brca-mutated-cancer
#20
Andrea E Wahner Hendrickson, Scott H Kaufmann, Elizabeth M Swisher
Immunotherapy is changing the landscape of cancer treatment. Nonetheless, not all malignancies respond, possibly due to low mutational load. Recent work in a TP53(-/-)BRCA1-mutant murine breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival after DNA damaging chemotherapy, whereas single blockade does not. These findings suggest an approach to enhance the impact of immune checkpoint blockade in BRCA-mutated tumors...
November 2017: Trends in Cancer
keyword
keyword
56488
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"